Last week, Senate Finance Committee Ranking Member Ron Wyden (D- Ore.) introduced the “Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017.” As its name suggests, it seeks to require parties (e.g., PBMs)...more
3/22/2017
/ Department of Health and Human Services (HHS) ,
Disclosure ,
Drug Pricing ,
Medicare Part D ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Rebates ,
Sensitive Business Information ,
State Health Insurance Exchanges ,
Transparency